Skip to main content
Erschienen in: Herz 3/2015

01.05.2015 | Original article

Evaluation of adiponectin and lipoprotein(a) levels in cardiac syndrome X

verfasst von: E. Guler, MD, G.B. Guler, F. Kizilirmak, U. Batgerel, G.G. Demir, H.M. Gunes, O. Karaca, Ö. Özcan, İ. Barutcu, M.M. Turkmen, A.M. Esen

Erschienen in: Herz | Sonderheft 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Aims

Low adiponectin and high lipoprotein(a) [Lp(a)] levels are associated with endothelial dysfunction, atherosclerosis, and coronary artery disease. Cardiac syndrome X (CSX) is characterized by anginal symptoms, positive stress test, and documentation of normal epicardial coronary arteries with angiography. In this study we aimed to investigate the relationship between CSX and circulating levels of adiponectin and Lp(a).

Patients and methods

We enrolled 53 female patients with CSX and 33 patients as the control group. The diagnosis of CSX was made according to presence of angina, findings suggestive of ischemia during stress electrocardiography or myocardial perfusion scintigraphy, and documentation of normal coronary arteries in coronary angiography. The control group consisted of patients with atypical angina and normal stress electrocardiography test results. Both groups were matched in terms of hypertension, diabetes mellitus, and metabolic syndrome.

Results

Adiponectin levels were significantly decreased in patients with CSX (4.57 μg/ml vs. 13.18 μg/ml; p=0.001); however, Lp(a) levels were significantly increased (36.30 mg/dl vs. 7.24 mg/dl; p < 0.001). Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) concentrations did not differ between the case group and the control group (p=0.14, p=0.62, p=0.64, respectively). There was no significant difference between groups in terms of age, body mass index, waist circumference hypertension, hyperlipidemia, diabetes mellitus, or metabolic syndrome. In multivariate analysis, Lp(a) and adiponectin were found to be independent predictors of CSX. An Lp(a) level of > 21 mg/dl had 84 % sensitivity and 96 % specificity {area under the curve (AUC)= 0.922, p < 0.0001, 95 % CI [0.842–0.970]} and an adiponectin level of ≤ 5.18 μg/ml also had 58.7 % sensitivity and 82.1 % specificity (AUC=0.726, p=0.0003, 95 % CI [0.609–0.823]) for detecting CSX.

Conclusion

We detected low adiponectin and high Lp(a) levels in patients with CSX and these findings may be related to the microvascular injury in CSX.
Literatur
1.
Zurück zum Zitat Cannon RO, Epstein SE (1988) “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 61:1338–1343CrossRefPubMed Cannon RO, Epstein SE (1988) “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 61:1338–1343CrossRefPubMed
2.
Zurück zum Zitat Kemp HG, Kronmal RA, Vlietstra RE, Frye RL (1986) Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 7:479–483CrossRefPubMed Kemp HG, Kronmal RA, Vlietstra RE, Frye RL (1986) Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 7:479–483CrossRefPubMed
3.
Zurück zum Zitat Mohri M, Koyanagi M, Egashira K et al (1998) Angina pectoris caused by coronary microvascular spasm. Lancet 351(9110):1165–1169CrossRefPubMed Mohri M, Koyanagi M, Egashira K et al (1998) Angina pectoris caused by coronary microvascular spasm. Lancet 351(9110):1165–1169CrossRefPubMed
4.
Zurück zum Zitat Piatti P, Fragasso G, Monti LD et al (1999) Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 34(5):1452–1460CrossRefPubMed Piatti P, Fragasso G, Monti LD et al (1999) Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 34(5):1452–1460CrossRefPubMed
6.
Zurück zum Zitat Cosin-Sales J, Pizzi C, Brown S, Kaski JC (2003) C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 41(9):1468–1474CrossRefPubMed Cosin-Sales J, Pizzi C, Brown S, Kaski JC (2003) C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 41(9):1468–1474CrossRefPubMed
7.
Zurück zum Zitat Tousoulis D, Davies GJ, Asimakopoulos G et al (2001) Vascular cell adhesion molecule-1and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 24:301–304CrossRefPubMed Tousoulis D, Davies GJ, Asimakopoulos G et al (2001) Vascular cell adhesion molecule-1and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 24:301–304CrossRefPubMed
9.
Zurück zum Zitat Funahashi T, Nakamura T, Shimomura I et al (1999) Role of adipo-cytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202–206CrossRefPubMed Funahashi T, Nakamura T, Shimomura I et al (1999) Role of adipo-cytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202–206CrossRefPubMed
10.
Zurück zum Zitat Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476CrossRefPubMed Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476CrossRefPubMed
11.
Zurück zum Zitat Wang ZV, Scherer PE (2008) Adiponectin, cardiovascular function, and hypertension. Hypertension 51:8–14CrossRefPubMed Wang ZV, Scherer PE (2008) Adiponectin, cardiovascular function, and hypertension. Hypertension 51:8–14CrossRefPubMed
12.
Zurück zum Zitat Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMed Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMed
13.
Zurück zum Zitat Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314:1–16CrossRefPubMed Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314:1–16CrossRefPubMed
14.
Zurück zum Zitat Brunner C, Kraft HG, Utermann G, Muller HJ (1993) Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A 90:11643–11647CrossRefPubMedCentralPubMed Brunner C, Kraft HG, Utermann G, Muller HJ (1993) Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A 90:11643–11647CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Sawabe M, Tanaka N, Nakahara K et al (2009) A high lipoprotein(a) level confers approximatel yequal positive effects on coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart (published online 25 Aug 2009) Sawabe M, Tanaka N, Nakahara K et al (2009) A high lipoprotein(a) level confers approximatel yequal positive effects on coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart (published online 25 Aug 2009)
16.
Zurück zum Zitat Erqou S, Kaptoge S, Perry PL et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412–423CrossRefPubMed Erqou S, Kaptoge S, Perry PL et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412–423CrossRefPubMed
17.
Zurück zum Zitat James L, Ritchie MD, Melvin D et al (1997) ACC/AHA Guidelines for the clinical application of echocardiography. Circulation 95:1686–1744CrossRef James L, Ritchie MD, Melvin D et al (1997) ACC/AHA Guidelines for the clinical application of echocardiography. Circulation 95:1686–1744CrossRef
18.
19.
Zurück zum Zitat Vesely MR, Dilsizian V (2011) Microvascular angina: assessment of coronary blood flow, flow reserve, and metabolism. Curr Cardiol Rep 13(2):151–158CrossRefPubMed Vesely MR, Dilsizian V (2011) Microvascular angina: assessment of coronary blood flow, flow reserve, and metabolism. Curr Cardiol Rep 13(2):151–158CrossRefPubMed
20.
Zurück zum Zitat Jadhav S, Ferrell W, Greer IA et al (2006) Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 48(5):956–963 (Epub 2006 Aug 17)CrossRefPubMed Jadhav S, Ferrell W, Greer IA et al (2006) Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 48(5):956–963 (Epub 2006 Aug 17)CrossRefPubMed
21.
Zurück zum Zitat Pasceri V, Lanza GA, Buffon A et al (1998) Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol 31(1):62–66CrossRefPubMed Pasceri V, Lanza GA, Buffon A et al (1998) Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol 31(1):62–66CrossRefPubMed
22.
23.
Zurück zum Zitat Kaski JC, Elliott PM, Salomone O et al (1995) Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 74:620–624CrossRefPubMedCentralPubMed Kaski JC, Elliott PM, Salomone O et al (1995) Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 74:620–624CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Panting JR, Gatehouse PD, Yang GZ et al (2002) Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular resonance imaging. N Engl J Med 346:1948–1953CrossRefPubMed Panting JR, Gatehouse PD, Yang GZ et al (2002) Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular resonance imaging. N Engl J Med 346:1948–1953CrossRefPubMed
25.
Zurück zum Zitat Kadowaki T, Yamauchi T, Kubota N et al (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792CrossRefPubMedCentralPubMed Kadowaki T, Yamauchi T, Kubota N et al (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491CrossRefPubMed Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487–37491CrossRefPubMed
27.
Zurück zum Zitat Porro B, Eligini S, Veglia F et al (2014) Nitric oxide synthetic pathway in patients with microvascular angina and its relations with oxidative stress. Oxid Med Cell Longev 2014:726539CrossRefPubMedCentralPubMed Porro B, Eligini S, Veglia F et al (2014) Nitric oxide synthetic pathway in patients with microvascular angina and its relations with oxidative stress. Oxid Med Cell Longev 2014:726539CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Chen H, Montagnani M, Funahashi T et al (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021–45026CrossRefPubMed Chen H, Montagnani M, Funahashi T et al (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021–45026CrossRefPubMed
29.
Zurück zum Zitat Ohta H, Wada H, Niwa T et al (2005) Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 180:11–17CrossRefPubMed Ohta H, Wada H, Niwa T et al (2005) Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 180:11–17CrossRefPubMed
30.
Zurück zum Zitat Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypo-adiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89CrossRefPubMed Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypo-adiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89CrossRefPubMed
31.
Zurück zum Zitat Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599CrossRefPubMed Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599CrossRefPubMed
32.
Zurück zum Zitat Shibata R, Ouchi N, Ito M et al (2004) Adiponectin-mediatedmodulationof hypertrophic signals in theheart. Nature 10:1384–1389 Shibata R, Ouchi N, Ito M et al (2004) Adiponectin-mediatedmodulationof hypertrophic signals in theheart. Nature 10:1384–1389
33.
Zurück zum Zitat Mitsuhashi H, Yatsuya H, Tamakoshi K et al (2007) Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension 49:1448–1454CrossRefPubMed Mitsuhashi H, Yatsuya H, Tamakoshi K et al (2007) Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension 49:1448–1454CrossRefPubMed
34.
Zurück zum Zitat Beisiegel U, Niendorf A, Wolf K et al (1990) Liporotein (a) in the arterial wall. Eur Heart J 11(Suppl E):174–183CrossRefPubMed Beisiegel U, Niendorf A, Wolf K et al (1990) Liporotein (a) in the arterial wall. Eur Heart J 11(Suppl E):174–183CrossRefPubMed
35.
Zurück zum Zitat Marcovina SM, Koschinsky ML (2003) Evaluation of lipoprotein(a) as a pro-thrombotic factor: progress from bench to bedside. Curr Opin Lipidol 14:361–366CrossRefPubMed Marcovina SM, Koschinsky ML (2003) Evaluation of lipoprotein(a) as a pro-thrombotic factor: progress from bench to bedside. Curr Opin Lipidol 14:361–366CrossRefPubMed
36.
37.
Zurück zum Zitat Liu QM, Zhou SH, Qi SS et al (2008) Significance of the lipid profile and endothelium—dependent vasodilatation in the pathogenesis of microvascular angına. Cardiol J 15(4):324–328PubMed Liu QM, Zhou SH, Qi SS et al (2008) Significance of the lipid profile and endothelium—dependent vasodilatation in the pathogenesis of microvascular angına. Cardiol J 15(4):324–328PubMed
38.
Zurück zum Zitat Bostom AG, Gagnon DR, Cupples LA et al (1994) A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women The Framingham Heart Study. Circulation 90:1688–1695CrossRefPubMed Bostom AG, Gagnon DR, Cupples LA et al (1994) A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women The Framingham Heart Study. Circulation 90:1688–1695CrossRefPubMed
39.
Zurück zum Zitat Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC (2013) Inflammation and microvascular dysfunction in cardiac syndrome x patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 6(6):660–667CrossRefPubMed Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC (2013) Inflammation and microvascular dysfunction in cardiac syndrome x patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 6(6):660–667CrossRefPubMed
40.
Zurück zum Zitat Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30:8–13CrossRefPubMed Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30:8–13CrossRefPubMed
41.
Zurück zum Zitat Mannucci E, Monami M, Bardini G et al (2007) National Cholesterol Educational Program and International Diabetes Federation diag-nostic criteria for metabolic syndrome in an Italian cohort: results from the FIBAR Study. J Endocrinol Invest 30:925–930CrossRefPubMed Mannucci E, Monami M, Bardini G et al (2007) National Cholesterol Educational Program and International Diabetes Federation diag-nostic criteria for metabolic syndrome in an Italian cohort: results from the FIBAR Study. J Endocrinol Invest 30:925–930CrossRefPubMed
42.
Zurück zum Zitat Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689CrossRefPubMed Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689CrossRefPubMed
43.
Zurück zum Zitat Montalescot G, Sechtem U, Achenbach S et al (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34(38):2949–3003CrossRefPubMed Montalescot G, Sechtem U, Achenbach S et al (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34(38):2949–3003CrossRefPubMed
Metadaten
Titel
Evaluation of adiponectin and lipoprotein(a) levels in cardiac syndrome X
verfasst von
E. Guler, MD
G.B. Guler
F. Kizilirmak
U. Batgerel
G.G. Demir
H.M. Gunes
O. Karaca
Ö. Özcan
İ. Barutcu
M.M. Turkmen
A.M. Esen
Publikationsdatum
01.05.2015
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe Sonderheft 3/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-014-4191-1

Weitere Artikel der Sonderheft 3/2015

Herz 3/2015 Zur Ausgabe

Übersichtsarbeit

Epikardiales Fett

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.